Clinical assessment of Super bioavailable Itraconazole 50 mg in dermatophytosis (Clear 50)

---

Original Article

Author Details : Sunil Ghate, Dhiraj Dhoot*, Harshal Mahajan, Hanmant Barkate

Volume : 7, Issue : 2, Year : 2021

Article Page : 125-129

https://doi.org/10.18231/j.ijced.2021.024

Suggest article by email

Get Permission

---

Abstract

Introduction: Super bioavailable itraconazole (SBITZ) is a newer formulation of itraconazole which is recently launched in India. But there is no published clinical evidence of SBITZ in the management of dermatophytosis in Indian patients.
Materials and Methods: A Real world retrospective data analysis was conducted with 346 dermatologists across India to assess the response of Indian patients with dermatophytosis who were prescribed super bioavailable itraconazole 50 mg twice a day for 4 weeks.
Results: Out of 4625 patients’ data, 2743 were included for final analysis. Mean age of patients was 36.1712.05 years with male preponderance. Most of the patients were diagnosed as T. cruris. At the end of treatment, 51% of patients achieved complete clinical cure while 46% achieved clinical improvement (>50% symptom clearance) and 3% were labelled as clinical failure. About 70% patients achieved clearance in body surface area. Mean total symptom score (TSS) was reduced to 0.741.1 from 7.291.73 while mean BSA score was reduced from 1.960.83 to 0.380.65 (p<0> Conclusion: Patients treated with super bioavailable itraconazole showed greater improvement in clearance of symptoms as well as lesions. Additionally, it showed significant improvement in naïve, recurrent and chronic patients enabling its placement in armamentarium of management of all types of dermatophytosis.

Keywords: Super bioavailable itraconazole, Chronic, Naïve, Recurrent, BSA, Real world.

How to cite : Ghate S , Dhoot D , Mahajan H , Barkate H , Clinical assessment of Super bioavailable Itraconazole 50 mg in dermatophytosis (Clear 50). IP Indian J Clin Exp Dermatol 2021;7(2):125-129

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.